Liver fibrosis in biliary atresia

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 3, 2010, Pages 335-343

  Haafiz, Allah B ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antifibrotic therapy; Biliary atresia; Biliary epithelial cell; Hepatic fibrogenesis; Hepatic stellate cell

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CORTICOSTEROID; PLACEBO; TRANSFORMING GROWTH FACTOR BETA1; URSODEOXYCHOLIC ACID;

APOPTOSIS; BILE DUCT ATRESIA; CHOLANGITIS; CHOLESTASIS; ELASTOGRAPHY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROGENESIS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MYOFIBROBLAST; OXIDATIVE STRESS; PATHOGENESIS; PORTOENTEROSTOMY; PROGNOSIS; REVIEW; STELLATE CELL; TISSUE REPAIR; BILIARY ATRESIA; CHILD; INFANT; NEWBORN; PATHOLOGY; PRESCHOOL CHILD;

BILIARY ATRESIA; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; OXIDATIVE STRESS;

EID: 77953237092     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.29     Document Type: Review

References (103)

1. Balistreri WF, Grand R, Hoofnagle JH et al. Biliary atresia: current concepts and research directions - summary of a symposium. Hepatology 23, 1682-1692 (1996).
2. Chang HK, Park YJ, Koh H et al. Hepatic fibrosis scan for liver stiffness score measurement: a useful preendoscopic screening test for the detection of varices in postoperative patients with biliary atresia. J. Pediatr. Gastroenterol. Nutr. 49, 323-328 (2009).
3. McKiernan PJ, Baker AJ, Kelly DA. The frequency and outcome of biliary atresia in the UK and Ireland. Lancet 355, 25-29 (2000).
4. Mills CO, Milkiewicz P, Muller M et al. Different pathways of canalicular secretion of sulfated and non-sulfated fluorescent bile acids: a study in isolated hepatocyte couplets and TR-rats. J. Hepatol. 31, 678-684 (1999).
5. Yoon PW, Bresee JS, Olney RS, James LM, Khoury MJ. Epidemiology of biliary atresia: a population-based study. Pediatrics 99, 376-382 (1997).
6. Narkewicz MR. Biliary atresia: an update on our understanding of the disorder. Curr. Opin. Pediatr. 13, 435-440 (2001).
7. Perlmutter DH, Shepherd RW. Extrahepatic biliary atresia: a disease or a phenotype? Hepatology 35, 1297-1304 (2002).
8. Davenport M, Howard ER. Macroscopic appearance at portoenterostomy - a prognostic variable in biliary atresia. J. Pediatr. Surg. 31, 1387-1390 (1996).
9. Shteyer E, Ramm GA, Xu C, White FV, Shepherd RW. Outcome after portoenterostomy in biliary atresia: pivotal role of degree of liver fibrosis and intensity of stellate cell activation. J. Pediatr. Gastroenterol. Nutr. 42, 93-99 (2006).
10. Weerasooriya VS, White FV, Shepherd RW. Hepatic fibrosis and survival in biliary atresia. J. Pediatr. 144, 123-125 (2004).
11. Hartley JL, Davenport M, Kelly DA. Biliary atresia. Lancet 374, 1704-1713 (2009).
12. Adrian JE, Kamps JAAM, Scherphof GL et al. A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stellate cells, in the fibrotic livers of bile duct ligated rats. Biochim. Biophys. Acta 1768, 1430-1439 (2007).
13. Bolkenius U, Hahn D, Gressner AM, Breitkopf K, Dooley S, Wickert L. Glucocorticoids decrease the bioavailability of TGF-b which leads to a reduced TGF-b signaling in hepatic stellate cells. Biochem. Biophys. Res. Commun. 325, 1264-1270 (2004).
14. Caligiuri A, De Franco RM, Romanelli RG et al. Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology 124, 504-520 (2003).
15. Caligiuri A, De Franco RM, Romanelli RG et al. Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology 124, 504-520 (2003).
16. Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J. Hepatol. 36, 200-209 (2002).
17. Chen A, Beno DW, Davis BH. Suppression of stellate cell type I collagen gene expression involves AP-2 transmodulation of nuclear factor-1-dependent gene transcription. J. Biol. Chem. 271, 25994-25998 (1996).
18. Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124, 105-117 (2003).
19. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348, 800-807 (2003).
20. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 339, 61-68 (1998).
21. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon a-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122, 1303-1313 (2002).
22. Chojkier M, Houglum K, Solis-Herruzo J, Brenner DA. Stimulation of collagen gene expression by ascorbic acid in cultured human fibroblasts. A role for lipid peroxidation? J. Biol. Chem. 264, 16957-16962 (1989).
23. Chen A, Davis BH. The DNA binding protein BTEB mediates acetaldehyde-induced, jun N-terminal kinase-dependent aI(I) collagen gene expression in rat hepatic stellate cells. Mol. Cell. Biol. 20, 2818-2826 (2000).
24. Garcia-Trevijano ER, Iraburu MJ, Fontana L et al. Transforming growth factor b1 induces the expression of a1(I) procollagen mRNA by a hydrogen peroxide-C/EBPb-dependent mechanism in rat hepatic stellate cells. Hepatology 29, 960-970 (1999).
25. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF a and collagen type I is mediated by oxidative stress through c-myb expression. J. Clin. Invest. 96, 2461-2468 (1995).
26. Kim Y, Ratziu V, Choi SG, Lalazar A et al. Transcriptional activation of transforming growth factor b1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. J. Biol. Chem. 273, 33750-33758 (1998).
27. Kojima S, Hayashi S, Shimokado K et al. Transcriptional activation of urokinase by the Kruppel-like factor Zf9/COPEB activates latent TGF-b1 in vascular endothelial cells. Blood 95, 1309-1316 (2000).
28. Comporti M, Arezzini B, Signorini C, Sgherri C, Monaco B, Gardi C. F2-isoprostanes stimulate collagen synthesis in activated hepatic stellate cells: a link with liver fibrosis? Lab. Invest. 85, 1381-1391 (2005).
29. Gujral JS, Liu J, Farhood A, Hinson JA, Jaeschke H. Functional importance of ICAM-1 in the mechanism of neutrophil-induced liver injury in bile duct-ligated mice. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G499-G507 (2004).
30. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 43, S31-S44 (2006).
31. Rodrigues CM, Steer CJ. Mitochondrial membrane perturbations in cholestasis. J. Hepatol. 32, 135-141 (2000).
32. Sokol RJ, Devereaux MW, Khandwala R. Effect of oxypurinol, a xanthine oxidase inhibitor, on hepatic injury in the bile duct-ligated rat. Pediatr. Res. 44, 397-401 (1998).
33. Kawamura K, Kobayashi Y, Kageyama F et al. Enhanced hepatic lipid peroxidation in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 95, 3596-3601 (2000).
34. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol. Appl. Pharmacol. 202, 199-211 (2005).
35. Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin. Liver Dis. 25, 433-449 (2005).
36. Shim H, Harris ZL. Genetic defects in copper metabolism. J. Nutr. 133, 1527S-1531S (2003).
37. Desmet V, Roskams T, Van EP. Ductular reaction in the liver. Pathol. Res. Pract. 191, 513-524 (1995).
38. Roskams T, Desmet V. Ductular reaction and its diagnostic significance. Semin. Diagn. Pathol. 15, 259-269 (1998).
39. LeSage G, Glaser S, Alpini G. Regulation of cholangiocyte proliferation. Liver 21, 73-80 (2001).
40. Slott PA, Liu MH, Tavoloni N. Origin, pattern, and mechanism of bile duct proliferation following biliary obstruction in the rat. Gastroenterology 99, 466-477 (1990).
41. Polimeno L, Azzarone A, Zeng QH et al. Cell proliferation and oncogene expression after bile duct ligation in the rat: evidence of a specific growth effect on bile duct cells. Hepatology 21, 1070-1078 (1995).
42. Alvaro D, Mancino MG, Glaser S et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 132, 415-431 (2007).
43. Diaz R, Kim JW, Hui JJ et al. Evidence for the epithelial to mesenchymal transition in biliary atresia fibrosis. Hum. Pathol. 39, 102-115 (2008).
44. Greenbaum LE, Wells RG. The role of stem cells in liver repair and fibrosis. Int. J. Biochem. Cell Biol. DOI:10.1016/j. biocel.2009.11.006 (2009) (Epub ahead of print).
45. Libbrecht L, Desmet V, Van DB, Roskams T. Deep intralobular extension of human hepatic 'progenitor cells' correlates with parenchymal inflammation in chronic viral hepatitis: can 'progenitor cells' migrate? J. Pathol. 192, 373-378 (2000).
46. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am. J. Pathol. 154, 537-541 (1999).
47. Petersen BE, Bowen WC, Patrene KD et al. Bone marrow as a potential source of hepatic oval cells. Science 284, 1168-1170 (1999).
48. Preisegger KH, Factor VM, Fuchsbichler A, Stumptner C, Denk H, Thorgeirsson SS. Atypical ductular proliferation and its inhibition by transforming growth factor b1 in the 3,5-diethoxycarbonyl-1,4- dihydrocollidine mouse model for chronic alcoholic liver disease. Lab. Invest. 79, 103-109 (1999).
49. Yang L, Faris RA, Hixson DC. Characterization of a mature bile duct antigen expressed on a subpopulation of biliary ductular cells but absent from oval cells. Hepatology 18, 357-366 (1993).
50. Yang L, Faris RA, Hixson DC. Phenotypic heterogeneity within clonogenic ductal cell populations isolated from normal adult rat liver. Proc. Soc. Exp. Biol. Med. 204, 280-288 (1993).
51. Kinnman N, Housset C. Peribiliary myofibroblasts in biliary type liver fibrosis. Front. Biosci. 7, d496-d503 (2002).
52. Magness ST, Bataller R, Yang L, Brenner DA. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 40, 1151-1159 (2004).
53. Forbes SJ, Russo FP, Rey V et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 126, 955-963 (2004).
54. Suskind DL, Muench MO. Searching for common stem cells of the hepatic and hematopoietic systems in the human fetal liver: CD34+ cytokeratin 7/8+ cells express markers for stellate cells. J. Hepatol. 40, 261-268 (2004).
55. Dalakas E, Newsome PN, Boyle S et al. Bone marrow stem cells contribute to alcohol liver fibrosis in humans. Stem Cells Dev. DOI:10.1089/scd.2009.0387 (2009) (Epub ahead of print).
56. Kisseleva T, Uchinami H, Feirt N et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J. Hepatol. 45, 429-438 (2006).
57. Russo FP, Alison MR, Bigger BW et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 130, 1807-1821 (2006).
58. Del CG, Murillo MM, Avarez-Barrientos A et al. Autocrine production of TGF-b confers resistance to apoptosis after an epithelial-mesenchymal transition process in hepatocytes: role of EGF receptor ligands. Exp. Cell Res. 312, 2860-2871 (2006).
59. Ju W, Ogawa A, Heyer J et al. Deletion of Smad2 in mouse liver reveals novel functions in hepatocyte growth and differentiation. Mol. Cell. Biol. 26, 654-667 (2006).
60. Kaimori A, Potter J, Kaimori JY, Wang C, Mezey E, Koteish A. Transforming growth factor-b1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J. Biol. Chem. 282, 22089-22101 (2007).
61. Kojima T, Takano K, Yamamoto T et al. Transforming growth factor-b induces epithelial to mesenchymal transition by down-regulation of claudin-1 expression and the fence function in adult rat hepatocytes. Liver Int. 28, 534-545 (2008).
62. Valdes F, Alvarez AM, Locascio A et al. The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor b in fetal rat hepatocytes. Mol. Cancer Res. 1, 68-78 (2002).
63. Zeisberg M, Yang C, Martino M et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J. Biol. Chem. 282, 23337-23347 (2007).
64. Mack CL, Falta MT, Sullivan AK et al. Oligoclonal expansions of CD4+ and CD8+ T-cells in the target organ of patients with biliary atresia. Gastroenterology 133, 278-287 (2007).
65. Ohya T, Fujimoto T, Shimomura H, Miyano T. Degeneration of intrahepatic bile duct with lymphocyte infiltration into biliary epithelial cells in biliary atresia. J. Pediatr. Surg. 30, 515-518 (1995).
66. Schweizer P, Petersen M, Jeszberger N, Ruck P, Dietz K. Immunohistochemical and molecular biological investigations regarding the pathogenesis of extrahepatic biliary atresia. (Part 1: immunohistochemical studies). Eur. J. Pediatr. Surg. 13, 7-15 (2003).
67. Ahmed AF, Ohtani H, Nio M et al. CD8+ T cells infiltrating into bile ducts in biliary atresia do not appear to function as cytotoxic T cells: a clinicopathological analysis. J. Pathol. 193, 383-389 (2001).
68. Dillon P, Belchis D, Tracy T, Cilley R, Hafer L, Krummel T. Increased expression of intercellular adhesion molecules in biliary atresia. Am. J. Pathol. 145, 263-267 (1994).
69. Dillon PW, Belchis D, Minnick K, Tracy T. Differential expression of the major histocompatibility antigens and ICAM-1 on bile duct epithelial cells in biliary atresia. Tohoku J. Exp. Med. 181, 33-40 (1997).
70. Kobayashi H, Puri P, O'Briain DS, Surana R, Miyano T. Hepatic overexpression of MHC class II antigens and macrophage-associated antigens (CD68) in patients with biliary atresia of poor prognosis. J. Pediatr. Surg. 32, 590-593 (1997).
71. Shivakumar P, Campbell KM, Sabla GE et al. Obstruction of extrahepatic bile ducts by lymphocytes is regulated by IFN-g in experimental biliary atresia. J. Clin. Invest. 114, 322-329 (2004).
72. Shivakumar P, Sabla G, Mohanty S et al. Effector role of neonatal hepatic CD8+ lymphocytes in epithelial injury and autoimmunity in experimental biliary atresia. Gastroenterology 133, 268-277 (2007).
73. Muraji T, Suskind DL, Irie N. Biliary atresia: a new immunological insight into etiopathogenesis. Expert Rev. Gastroenterol. Hepatol. 3, 599-606 (2009).
74. Balistreri WF, Grand R, Hoofnagle JH et al. Biliary atresia: current concepts and research directions - summary of a symposium. Hepatology 23, 1682-1692 (1996).
75. Liu C, Chiu JH, Chin T et al. Expression of fas ligand on bile ductule epithelium in biliary atresia - a poor prognostic factor. J. Pediatr. Surg. 35, 1591-1596 (2000).
76. Sokol RJ, Mack C. Etiopathogenesis of biliary atresia. Semin. Liver Dis. 21, 517-524 (2001).
77. Urushihara N, Iwagaki H, Yagi T et al. Elevation of serum interleukin-18 levels and activation of Kupffer cells in biliary atresia. J. Pediatr. Surg. 35, 446-449 (2000).
78. Davenport M, Gonde C, Redkar R et al. Immunohistochemistry of the liver and biliary tree in extrahepatic biliary atresia. J. Pediatr. Surg. 36, 1017-1025 (2001).
79. Ramm GA, Nair VG, Bridle KR, Shepherd RW, Crawford DH. Contribution of hepatic parenchymal and nonparenchymal cells to hepatic fibrogenesis in biliary atresia. Am. J. Pathol. 153, 527-535 (1998).
80. Faiz Kabir Uddin Ahmed A, Ohtani H, Nio M et al. In situ expression of fibrogenic growth factors and their receptors in biliary atresia: comparison between early and late stages. J. Pathol. 192, 73-80 (2000).
81. Seki E, De MS, Osterreicher CH et al. TLR4 enhances TGF-b signaling and hepatic fibrosis. Nat. Med. 13, 1324-1332 (2007).
82. Duffield JS, Forbes SJ, Constandinou CM et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest. 115, 56-65 (2005).
83. Rivera CA, Bradford BU, Hunt KJ et al. Attenuation of CCl(4)-induced hepatic fibrosis by GdCl(3) treatment or dietary glycine. Am. J. Physiol. Gastrointest. Liver Physiol. 281, G200-G207 (2001).
84. Lamireau T, Le BB, Boussarie L et al. Expression of collagens type I and IV, osteonectin and transforming growth factor b-1 (TGFb1) in biliary atresia and paucity of intrahepatic bile ducts during infancy. J. Hepatol. 31, 248-255 (1999).
85. Pape L, Olsson K, Petersen C, von Wasilewski R, Melter M. Prognostic value of computerized quantification of liver fibrosis in children with biliary atresia. Liver Transpl. 15, 876-882 (2009).
86. Tanano H, Hasegawa T, Kimura T et al. Proposal of fibrosis index using image analyzer as a quantitative histological evaluation of liver fibrosis in biliary atresia. Pediatr. Surg. Int. 19, 52-56 (2003).
87. Abdi W, Millan JC, Mezey E. Sampling variability on percutaneous liver biopsy. Arch. Intern. Med. 139, 667-669 (1979).
88. Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol. 97, 2614-2618 (2002).
89. Tamatani T, Kobayashi H, Tezuka K et al. Establishment of the enzyme-linked immunosorbent assay for connective tissue growth factor (CTGF) and its detection in the sera of biliary atresia. Biochem. Biophys. Res. Commun. 251, 748-752 (1998).
90. Jiang CB, Lee HC, Yeung CY et al. A scoring system to predict the need for liver transplantation for biliary atresia after Kasai portoenterostomy. Eur. J. Pediatr. 162, 603-606 (2003).
91. Olthoff KM, Brown RS Jr, Delmonico FL et al. Summary report of a national conference: evolving concepts in liver allocation in the MELD and PELD era. December 8, (2003), Washington, DC, USA. Liver Transpl. 10, A6-A22 (2004).
92. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 134, 1670-1681 (2008).
93. Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med. Biol. 29, 1705-1713 (2003).
94. de Lédinghen V, Le Bail B, Rebouissoux L et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J. Pediatr. Gastroenterol. Nutr. 45, 443-450 (2007).
95. Huwart L, Salameh N, ter Beek L et al. MR elastography of liver fibrosis: preliminary results comparing spin-echo and echo-planar imaging. Eur. Radiol. 18, 2535-2541 (2008).
96. Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem. J. 411, 1-18 (2008).
97. Ghiassi-Nejad Z, Friedman SL. Advances in antifibrotic therapy. Expert Rev. Gastroenterol. Hepatol. 2, 803-816 (2008).
98. Kotb MA. Review of historical cohort: ursodeoxycholic acid in extrahepatic biliary atresia. J. Pediatr. Surg. 43, 1321-1327 (2008).
99. Willot S, Uhlen S, Michaud L et al. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia. Pediatrics 122, e1236-e1241 (2008).
100. Escobar MA, Jay CL, Brooks RM et al. Effect of corticosteroid therapy on outcomes in biliary atresia after Kasai portoenterostomy. J. Pediatr. Surg. 41, 99-103 (2006).
101. Meyers RL, Book LS, O'Gorman MA et al. High-dose steroids, ursodeoxycholic acid, and chronic intravenous antibiotics improve bile flow after Kasai procedure in infants with biliary atresia. J. Pediatr. Surg. 38, 406-411 (2003).
102. Davenport M, Stringer MD, Tizzard SA, McClean P, Mieli-Vergani G, Hadzic N. Randomized, double-blind, placebo-controlled trial of corticosteroids after Kasai portoenterostomy for biliary atresia. Hepatology 46, 1821-1827 (2007).
103. Muraji T, Higashimoto Y. The improved outlook for biliary atresia with corticosteroid therapy. J. Pediatr. Surg. 32, 1103-1106 (1997).